Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 10Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Other hematologic neoplasm 2Myeloid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Other neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 100Nivolumab 69Cyclophosphamide 67Ipilimumab 66fludarabine 34aldesleukin 29fludarabine phosphate 28Vemurafenib 28Interleukin-2 26trametinib 20Biopsy 20dabrafenib 17Radiotherapy 16Temozolomide 15Cisplatin 15Magnetic Resonance Spectroscopy 14Gemcitabine 14Filgrastim 14atezolizumab 13Specimen Handling 13Carboplatin 13CTLA-4 Antigen 13spartalizumab 12romidepsin 12Paclitaxel 12Bortezomib 11poly ICLC 10cobimetinib 10Peripheral Blood Stem Cell Transplantation 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Interferon-alpha × Dermatologic × Clear all
NCT00004244 2013-03-21

Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡